Thalidomide as a targeted therapy for multiple myeloma

Internal Medicine

Volumn 42, Issue 7, 2003, Pages 550-551

  Dan, Kazuo ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Angiogenesis; Immunomodulatory analogues; Multiple myeloma; Thalidomide

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BORTEZOMIB; CYTOKINE; FIBROBLAST GROWTH FACTOR; GAMMA INTERFERON; HEMOGLOBIN; IMMUNOGLOBULIN D; INTERLEUKIN 2; INTERLEUKIN 6; LENALIDOMIDE; PROTEASOME INHIBITOR; THALIDOMIDE; THALIDOMIDE DERIVATIVE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; APOPTOSIS; BONE MARROW; CANCER SURVIVAL; CELL COUNT; CELL CULTURE; CELL CYCLE G1 PHASE; CELL FUNCTION; CONSTIPATION; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE RELEASE; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG TARGETING; EDITORIAL; FATIGUE; FOLLOW UP; GROWTH INHIBITION; HEMATOLOGIC DISEASE; HEMODIALYSIS; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; LIMB DEFECT; MULTIPLE MYELOMA; MUSCLE WEAKNESS; NATURAL KILLER CELL; NEUROPATHY; PLASMA CELL; PROGNOSIS; RELAPSE; REMISSION; SOMNOLENCE; STEM CELL TRANSPLANTATION; TERATOGENICITY; TREATMENT OUTCOME;

EID: 0041670944     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.42.550     Document Type: Editorial

References (15)

1. Blade J, San Miguel JF, Montserrat F, et al. Survival of multiple myeloma patients who are potential candidates for early high-dose therapy intensification/autotransplantation and who were conventionally treated. J Clin Oncol 14: 2167-2173, 1996.
2. Palumbo A, Triolo S, Argentino C, et al. Dose-intensive melphalan with stem-cell support (MEL 100) is superior to standard treatment in elderly myeloma patients. Blood 94: 1248-1253, 1999.
3. Tricot G, Jagannath S, Vesole DH, Crowley J, Barlogie B. Relapse of multiple myeloma after autologous transplantation: survival after salvage therapy. Bone Marrow Transplant 16: 7-11, 1995.
4. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 335: 91-97, 1996.
5. Ribatti D, Vacca A, Nico B, et al. Bone marrow antiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma. Br J Cancer 79: 451-455, 1999.
6. Vacca A, Ribatti D, Presta M, et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 93: 3064-3073, 1999.
7. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91: 4082-4085, 1994.
8. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341: 1565-1571, 1999.
9. Hayashi T, Yamaguchi I, Saitoh H, Takagi M, Nonaka Y, Nomura T. Thalidomide treatment for immunoglobulin D multiple myeloma in a patient on chronic hemodialysis. Intern Med 42: 605-608, 2003.
10. Hales BF. Thalidomide on the comeback trail. Nat Med 5: 489-490, 1999.
11. Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 96: 2943-2950, 2000.
12. Gupta D, Treon SP, Shima Y, et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 15: 1950-1961, 2001.
13. Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 98: 210-216, 2001.
14. Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100: 3063-3067, 2002.
15. Anderson KC. Targeting the myeloma cell and its microenvironment. in: Hematology 2002 (American Society of Hematology Education Program Book), 2002: 232-240.